Lung volume reduction for emphysema comes of age
BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n14 (Published 11 January 2021) Cite this as: BMJ 2021;372:n14- Nicholas S Hopkinson, reader in respiratory medicine
- National Heart and Lung Institute, Imperial College London, London SW3 6NP, UK
- n.hopkinson{at}ic.ac.uk
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality, affecting around 4% of the global population1 and over 1.3 million people in the UK. The main symptoms are breathlessness, which limits everyday activities and is caused by airflow obstruction and lung hyperinflation, and cough with sputum. Despite conventional pharmacological approaches and addressing what the National Institute for Health and Care Excellence has defined as the “five fundamentals of COPD care”—smoking cessation, vaccination, pulmonary rehabilitation, self-management, and managing multimorbidity2—many people with the condition remain highly symptomatic.34
COPD encompasses a range of conditions, including chronic bronchitis, emphysema, and pulmonary vascular disease, some or all of which can occur to a variable extent in any one patient. Pharmacotherapy guidance is relatively undifferentiated, beyond a need to identify which patients are likely to benefit from inhaled corticosteroids.2 Although inhaled drugs can improve symptoms, a climate of therapeutic nihilism has prevailed because of the lack of treatments that alter the natural …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.